MNPR
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Monopar Therapeutics Inc.
- Nom
- Monopar Therapeutics Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $469.3M
- Employés
- 22
- PDG
- Chandler D. Robinson
- Site web
- https://www.monopartx.com
- Marché
- ADCTALXOATNMBCYCCMPXIMNM
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 51 920 titres (~4 769 907,16 $ US)
- Insiders
- STARR CHRISTOPHER MRobinson ChandlerTsuchimoto Kim RAnderson Raymond
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$388,523
Avg sell (VWAP, 90d window) $102.46 vs last close $83.98 (-18.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$388,523 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Thin $13,712,670/day · 20d vol
- Last synced
-
2026-10-08 21:10:41
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | STARR CHRISTOPHER M | Sell · S · 10b5-1 | 799 | $79.67 | $63,656 | Form 4 |
| 2026-09-24 | Robinson Chandler | Sell · S · 10b5-1 | 600 | $89.79 | $53,874 | Form 4 |
| 2026-08-26 | RIOUX PATRICE | Sell · S · 10b5-1 | 1 | $111.26 | $111 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | Sell · S · 10b5-1 | 590 | $113.84 | $67,166 | Form 4 |
| 2026-08-25 | Anderson Raymond | Sell · S · 10b5-1 | 1,802 | $113.05 | $203,716 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
MNPR is a pre-revenue, cash-burning company with deeply negative fundamentals (trend score: 15) that undermine its relatively strong liquidity position (85), which itself is only sustained through dilutive capital…
The first sentence of the analysis written for MNPR on 2026-10-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $389K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $389K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 51.35 · operating margin 0.0%
Suggested stop 72.33, nearest stored support minus 0.5 ATR(13.9% under the last close). Reward/risk to the next stored resistance is 1.42. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 51.353 | 11.475 | 4.172 | 4.208 | 12.984 | |
| Quick Ratio | 51.353 | 11.475 | 4.172 | 4.208 | 12.984 | |
| Solvency Ratio | -4.746 | -2.966 | -4.781 | -3.352 | -5.760 | |
| Cash Ratio | 22.606 | 8.720 | 4.135 | 2.616 | 12.846 | |
| Price To Earnings Ratio | -35.297 | -16.176 | -2.931 | -14.277 | -21.986 | |
| Price To Earnings Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Forward Price To Earnings Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Price To Earnings Diluted Ratio | -35.297 | -16.176 | -2.931 | -14.277 | -21.986 | |
| Price To Earnings Diluted Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Price To Book Ratio | 3.511 | 4.574 | 4.415 | 14.937 | 10.568 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -39.663 | -39.312 | -3.139 | -20.849 | -27.356 | |
| Price To Operating Cash Flow Ratio | -39.663 | -39.312 | -3.139 | -20.849 | -27.356 | |
| Debt To Assets Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Debt To Equity Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Debt To Capital Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.021 | 1.095 | 1.315 | 1.311 | 1.083 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.461 | -1.219 | -4.472 | -2.310 | -4.630 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -78.759 | 0.000 | 0.000 | -859.724 | 0.000 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -7,317,401.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -7,317,401.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -30.784 | -13.213 | -2.071 | -13.554 | -19.759 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 51.353 | ▲39.879 | ▲34.515 |
| Quick Ratio | 51.353 | ▲39.879 | ▲34.515 |
| Solvency Ratio | -4.746 | ▼-1.780 | ▼-0.425 |
| Cash Ratio | 22.606 | ▲13.886 | ▲12.422 |
| Price To Earnings Ratio | -35.297 | ▼-19.121 | ▼-17.164 |
| Price To Earnings Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Forward Price To Earnings Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Price To Earnings Diluted Ratio | -35.297 | ▼-19.121 | ▼-17.164 |
| Price To Earnings Diluted Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Price To Book Ratio | 3.511 | ▼-1.063 | ▼-4.090 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -39.663 | ▼-0.351 | ▼-13.599 |
| Price To Operating Cash Flow Ratio | -39.663 | ▼-0.351 | ▼-13.599 |
| Debt To Assets Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Capital Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.021 | ▼-0.074 | ▼-0.144 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.461 | ▼-3.242 | ▼-1.043 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | -0.000 | -0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -78.759 | ▼-78.759 | ▲108.938 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲1463480.200 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲1463480.200 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -30.784 | ▼-17.571 | ▼-14.908 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $483.9M | $251.8M | $24.7M | $150.7M | $200.2M | |
| Enterprise value | $422.3M | $205.9M | $17.4M | $142.5M | $179.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -34.61x | -32.16x | -2.21x | -19.72x | -24.58x | |
| EV / Free cash flow | -34.61x | -32.16x | -2.21x | -19.72x | -24.58x | |
| EV / EBITDA | -30.78x | -13.21x | -2.07x | -13.55x | -19.76x | |
| Net debt / EBITDA | 4.50x | 2.94x | 0.86x | 0.78x | 2.23x | |
| Current ratio | 51.35x | 11.47x | 4.17x | 4.21x | 12.98x | |
| Income quality | 0.89x | 0.41x | 0.94x | 0.69x | 0.80x | |
| Graham net-net | $19 | $5 | $0 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $137.7M | $55.0M | $5.6M | $10.0M | $18.9M | |
| Invested capital | $138.0M | $55.0M | $5.6M | $10.1M | $18.9M | |
| Return on assets | -9.7% | -25.9% | -114.4% | -79.5% | -44.4% | |
| Operating ROA | -16.6% | -47.8% | -85.9% | -62.4% | -48.8% | |
| Return on tangible assets | -9.7% | -25.9% | -114.4% | -79.5% | -44.4% | |
| Return on equity | -10.0% | -28.3% | -150.4% | -104.2% | -48.1% | |
| Return on invested capital | -12.1% | -29.4% | -158.0% | -104.3% | -48.2% | |
| Return on capital employed | -12.1% | -29.4% | -158.0% | -104.3% | -48.2% | |
| Earnings yield | -2.8% | -6.2% | -34.1% | -7.0% | -4.5% | |
| Free cash flow yield | -2.5% | -2.5% | -31.9% | -4.8% | -3.7% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-24 Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Profitability This table compares Regenicin and Monopar Therapeutics'' net
- 2026-08-19 Monopar Appoints Jeffrey D. Kent, M.D. WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.
- 2026-08-18 Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For ''Strong Buy'' Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming months is a major catalyst, with potential FDA approval and Priority Review Voucher upside. ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo and notable neurological improvement versus standard of care.
- 2026-08-13 Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
- 2026-08-12 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.
- 2026-07-22 Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted the first completed sections of the NDA.
- 2026-07-20 Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company''s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval.